<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hassanzadeh, A.</style></author><author><style face="normal" font="default" size="100%">Gorry, P. A.</style></author><author><style face="normal" font="default" size="100%">Morris, Gareth A.</style></author><author><style face="normal" font="default" size="100%">Barber, Jill</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pediatric erythromycins: a comparison of the properties of erythromycins A and B 2 '-ethyl succinates</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Chemistry</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%"><Go to ISI>://WOS:000241192400024</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">49</style></volume><pages><style face="normal" font="default" size="100%">6334-6342</style></pages><isbn><style face="normal" font="default" size="100%">0022-2623</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The antibiotic erythromycin A is generally administered to children as a suspension of the pro-drug erythromycin A 2'-ethyl succinate. The success of the pro-drug depends on (a) elimination of the unacceptably bitter taste of free erythromycin, (b) its stability against stomach acid, and (c) its smooth (base-catalyzed) hydrolysis in the body to yield active erythromycin. We have investigated the rates and pathways of acid-catalyzed degradation and base-catalyzed hydrolysis of the 2'-ethyl succinates of erythromycins A and B. Esterification does not protect the drugs against acid-catalyzed degradation in solution; however, erythromycin B 2'-ethyl succinate is much more stable than the corresponding erythromycin A ester, degrading nearly 40 times more slowly. The rates of base-catalyzed hydrolysis in conditions mimicking the blood stream are similar for the two pro-drugs. We conclude that erythromycin B 2'-ethyl succinate is an attractive prospect as a pediatric erythromycin pro-drug.</style></abstract><accession-num><style face="normal" font="default" size="100%">WOS:000241192400024</style></accession-num><notes><style face="normal" font="default" size="100%">Times Cited: 1</style></notes></record></records></xml>